A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia.
A retrospective case series of 12 smokers with schizophrenia or schizoaffective disorder who had not successfully quit smoking with previous treatments for tobacco dependence were treated with nicotine nasal spray. All but one patient (92 percent) tolerated the nasal spray well, and nine (75 percent) used it at maximal doses for prolonged periods. After treatment five patients (42 percent) were abstinent from smoking for more than 90 days, and four patients (33 percent) substantially reduced the amount that they smoked. Ten patients (83 percent) used the spray in combination with other medications, and all received psychosocial support. Nicotine nasal spray was found to be well tolerated.
Williams
Jill M
JM
Department of Psychiatry, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08855, USA. jill.williams@umdnj.edu
Ziedonis
Douglas M
DM
Foulds
Jonathan
J
D000281:Administration, Intranasal; D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D009538:Nicotine / Q000008:administration & dosage* / Q000627:therapeutic use; D016540:Smoking Cessation / Q000379:methods*; D012944:Social Support; D014029:Tobacco Use Disorder / Q000188:drug therapy*
D009538:Nicotine